Categories: News

NextMed Provides Statement Regarding Unaffiliated Entity With Same Name in Wall Street Journal Article

TUCSON, Ariz., March 29, 2023 (GLOBE NEWSWIRE) — Urology and lithotripsy services leader NextMed is issuing this statement in response to an article by the Wall Street Journal, published 4 March 2023, titled Startup Offering Ozempic Surges With Controversial Ads, Fake Testimonials, which reports on an entity that is being referred to by the same name, NextMed.

NextMed wishes to clarify that it is not affiliated in any way with Helio Logistics, Next Medical, or the URL www.NextMed.com. The companies mentioned in the Wall Street Journal article provide weight loss solutions. The content published in the article has no relevance to NextMed’s business.

NextMed is the only urology services provider in the United States with a comprehensive lithotripsy certification from the Accreditation Commission for Health Care (ACHC). NextMed adheres to high industry standards and operates with integrity across its businesses. It does not provide weight loss solutions in any form.

Founded in 1996, NextMed is currently headquartered in Tucson, AZ. NextMed is committed to providing its integrated urology platform and lithotripsy services of the highest quality to all urologists, facilities and patients.

Media Contact

Chris Gleason

CEO, NextMed

+1 520-547-4115

About NextMed

Founded in 1996, NextMed is a market leader in mobile outpatient urology services. As the first and only ACHC certified Comprehensive Lithotripsy provider in the market today NextMed provides proven best in class equipment and service through our comprehensive Integrated Urology Platform which includes: URS+, Lithotripsy, Uretersoscopy, ThuLEP/LAP, HoLEP/LAP, HIFU, PCR, FusionMRI, and more.

Staff

Recent Posts

Evotec Closes Sale of Just – Evotec Biologics’ Toulouse Site to Sandoz

All closing requirements satisfied following announcement of a non-binding term-sheet agreement in July and signing…

1 hour ago

RESPIREE SECURES SINGAPORE HSA APPROVAL FOR ITS AI-ENABLED 1BIO™AI SOFTWARE TO SUPPORT ACUTE DETERIORATION DETECTION

SINGAPORE, Dec. 7, 2025 /PRNewswire/ -- AI/ML health-tech startup Respiree has received approval from the Health…

4 hours ago

AI-for-Science Startup ChemLex Raises USD 45M, Launching Self-Driving Lab for Drug Discovery in Singapore

SINGAPORE, Dec. 7, 2025 /PRNewswire/ -- ChemLex, a next-generation AI-for-science company, today announced the establishment…

4 hours ago

Is The DEA in Systemic Collapse: Corruption, Constitutional Violations, and a Seven-Year War Against Marijuana Medical Science

The DEA was created to combat cartel trafficking, protect public health, and ensure researchers have…

19 hours ago

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology…

19 hours ago